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Abstract
Patients with breast cancer brain metastases have extremely limited survival and no approved 
systemic therapeutics. Triple negative breast cancer (TNBC) commonly metastasizes to the brain 
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and predicts poor prognosis. TNBC frequently harbors BRCA mutations translating to platinum 
sensitivity potentially augmented by additional suppression of DNA repair mechanisms through 
poly(ADP-ribose)polymerase (PARP) inhibition. We evaluated brain penetrance and efficacy of 
Carboplatin +/− the PARP inhibitor ABT888, and investigated gene expression changes in murine 
intracranial (IC) TNBC models stratified by BRCA and molecular subtype status.
Athymic mice were inoculated intra-cerebrally with BRCA-mutant: SUM149 (basal), MDA-
MB-436 (claudin-low), or BRCA-wild-type: MDA-MB-468 (basal), MDA-MB-231BR (claudin-
low) TNBC cells and treated with PBS control (IP, weekly), Carboplatin (50mg/kg/week, IP), 
ABT888 (25mg/kg/day, OG), or their combination. DNA-damage (γ-H2AX), apoptosis (cleaved-
Caspase-3(cC3)) and gene expression were measured in IC tumors.
Carboplatin+/−ABT888 significantly improved survival in BRCA-mutant IC models compared to 
control, but did not improve survival in BRCA-wild-type IC models. Carboplatin+ABT888 
revealed a modest survival advantage versus Carboplatin in BRCA-mutant models. ABT888 
yielded a marginal survival benefit in the MDA-MB-436, but not in the SUM149 model. BRCA-
mutant SUM149 expression of γ-H2AX and cC3 proteins was elevated in all treatment groups 
compared to Control, while BRCA-wild-type MDA-MB-468 cC3 expression did not increase with 
treatment. Carboplatin treatment induced common gene expression changes in BRCA-mutant 
models.
Carboplatin+/−ABT888 penetrates the brain and improves survival in BRCA-mutant IC TNBC 
models with corresponding DNA damage and gene expression changes. Combination therapy 
represents a potential promising treatment strategy for patients with TNBC brain metastases 
warranting further clinical investigation.
Introduction
Brain metastases are a particularly devastating complication for patients with triple negative 
breast cancer (TNBC) with a limited survival and few therapeutic options (1). TNBC lacks 
expression of the estrogen receptor (ER), the progesterone receptor (PR), and amplification 
of the human epidermal growth factor receptor 2 (HER-2) gene (2). When compared to other 
breast cancer subtypes, TNBC has an increased potential to spread to the central nervous 
system (CNS) (3–5); approximately 50% of patients with advanced TNBC will recur in the 
brain (4). Despite local cranial therapies (i.e. radiation and/or neurosurgery), overall survival 
from detection of CNS metastases for patients with TNBC is less than 6 months (1). 
Currently, there are no FDA-approved systemic or targeted therapies for patients with 
TNBC brain metastases. The treatment of CNS metastases arising from TNBC is limited by 
both the lack of defined biologic targets and the inability of the majority of anti-cancer 
agents to penetrate the blood brain barrier (BBB). Thus, there is an urgent need to develop 
safe and effective treatments for this aggressive disease.
Although TNBC is a distinct clinical subtype, it is a molecularly heterogeneous disease. 
Given the lack of defined biologic targets in TNBC, it is important to study possible 
molecular drivers to develop successful therapies. Gene expression studies have shown that 
greater than 75% of TNBC are basal-like or claudin-low subtype (6, 7). With approximately 
20% of TNBC patients harboring a mutation in either the BRCA1 or BRCA2 genes (8), 
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exploitation of this molecular pathway with brain penetrant cytotoxic agents could be used 
as a therapeutic strategy to treat TNBC brain metastases.
The BRCA family is responsible for repairing DNA double-stranded breaks (DSB) via 
homologous recombination (9). Thus, tumors harboring BRCA mutations are sensitized to 
DNA damaging cytotoxic agents such as platinum derivatives (i.e. cisplatin or carboplatin) 
that bind to DNA and form DNA crosslinks, leading to DNA DSBs (10). Following 
platinum treatment of BRCA-mutated breast cancer cells, at least two possibilities may 
occur: (1) the cells are unable to repair widespread DSBs and undergo apoptosis, or (2) the 
cells rely on the base excision machinery to rescue DSBs via the enzyme poly(ADP-
ribose)polymerase (PARP) (11, 12). One promising strategy to enhance the cytotoxic effect 
of platinum therapies in BRCA-mutated TNBC is concomitant PARP inhibition. This 
strategy may be particularly advantageous for TNBC BRCA-mutated brain metastases as 
several clinically-available PARP inhibitors cross the BBB (13).
Historically, platinums in combination with PARP inhibitors have shown activity in in vitro 
and in vivo models of BRCA-associated TNBC (14–16) and are brain penetrant. The 
combination of platinum/PARP inhibitor therapy has never been examined in breast cancer 
brain metastases. The novelty of this preclinical study is the exploration and efficacy of 
brain-permeable, clinically-available compounds in animal models of TNBC brain 
metastases, with the goal to translate these findings into the clinical setting. We present a 
novel study using preclinical murine models of intracranial TNBC, comparing both BRCA-
mutant (mut) and wild-type (wt) models, as well as basal-like and claudin-low subtypes in 
response to systemic platinum +/− PARP inhibitor combination therapy. This study uniquely 
demonstrates brain penetration of both systemically administered Carboplatin and ABT888, 
improved survival in BRCA-mut intracranial TNBC models, and molecular mechanisms of 
DNA damage and increased apoptosis in response to therapy. Our results suggest that 
Carboplatin+/−ABT888 may be a viable therapeutic option for patients with TNBC brain 
metastases.
Materials and Methods
Cell Lines and Culture Conditions
SUM149 (BRCA1-mut, basal-like), MDA-MB-436 (BRCA1-mut, claudin-low), MDA-
MB-468 (BRCA-wt, basal-like), and MDA-MB-231BR (BRCA-wt, claudin low) were 
selected for the study and obtained from the American Type Culture Collection unless 
otherwise specified. The identity of the cell lines was confirmed by gene expression 
(September 2010). All media and additives were purchased from Invitrogen (Grand Island, 
NY). SUM149 (17) was cultured in HuMEC with supplements and 5% fetal bovine serum 
(FBS). MDA-MB-468 was cultured in RPMI-1640 plus 10% FBS in a flask with plug seal 
cap (Corning, Tewksbury, MA). MDA-MB-231BR and MDA-MB-436 were maintained in 
DMEM (high glucose) plus 10% FBS. All cell lines except for MDA-MB-436 were 
transduced with pTK1261 vector carrying firefly Luciferase as previously described (18). 
Cell lines were maintained at 37°C and 5% carbon dioxide in the presence of Antibiotic-
Antimycotic solution (Invitrogen, Grand Island, NY). Cells were harvested immediately 
prior to intracranial implantation.
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Intracranial tumor implantation and animal handling
Ten week-old female Foxn1nu/nu mice (UNC Animal Studies Core) weighing at least 20 g 
before IC tumor implantation were used for all studies. IC tumor implantation was 
performed as previously described (18). All animals were handled and monitored for health 
conditions according to the Institutional Animal Care and Use Committee (IACUC) 
approved protocols and entered the study only if recovered following surgery. 
Bioluminescence imaging was performed weekly to monitor IC tumor growth as described 
previously (18).
Efficacy study design
For IC tumor models expressing Luciferase (SUM149, MDA-MB-468, MDA-MB-231BR), 
bioluminescence signal was used to evenly distribute tumor size among the treatment groups 
within each model. The average bioluminescence signal between treatment groups within 
each model was not statistically different prior to treatment (data not shown). MDA-MB-436 
injected animals were assigned to treatment groups randomly.
At 14 days following tumor implantation for all models except for MDA-MB-231BR (7 
days due to aggressive tumor phenotype), treatment started. Health and weight of the 
animals were monitored at least three times weekly until sacrifice due to clinical symptoms 
representing poor health condition (i.e. decreased response to stimuli, neurologic 
dysfunction, weight loss of 20%, and/or a Body Composition Score of 2 or less) or 12 weeks 
post-intracranial implantation as dictated by prespectified IACUC guidelines for humane 
reasons. Treatment doses were selected based on previous literature (16, 19, 20) and dose 
escalation studies (data not shown), and were: 100μl PBS control (IP, weekly), 50mg/kg/
week Carboplatin (IP) [10 mg/mL sterile aqueous solution, University of North Carolina 
Hospital Pharmacy, Chapel Hill, NC], 25mg/kg/day ABT888 (oral gavage (OG)) [Chemistry 
Center for Integrative Chemical Biology and Drug Discovery, UNC] dissolved in PBS (Life 
Technologies, Grand Island, NY) immediately prior to OG, or combination 50 mg/kg/week 
Carboplatin+25 mg/kg/day ABT888 (IP and OG respectively). For the SUM149 model, 
survival data from three independent experiments were combined based on similar median 
survival for all control groups (data not shown, p=0.35). No toxicities were found 
throughout the survival studies in any model or treatment group.
Magnetic Resonance Imaging and Analysis of Blood Brain Barrier Permeability
Four mice from each IC model were used. Gadolinium enhanced brain magnetic resonance 
imaging (MRI) on a BioSpec 9.4 T small animal imaging system (Bruker Corporation, 
Billerica, MA) under isoflurane anesthesia began one week following MDA-MB-231-BR 
injection and two weeks following SUM149, MDA-MB-436, and MDA-MB-468 injection. 
Precontrast coronal T1 and T2 images were obtained for localization. Pre-contrast variable 
flip angle gradaint echo T1 sequences (TE=1.5 msec, TR 15 msec, flip angles 2, 5, 10, and 
15 degrees) were performed followed by a dynamic scan using 15 degree flip angle was 
repeated for 130 scans (8.6 sec/repeat) for dynamic contrast enhancement. After the 5th scan, 
gadopentate dimeglumine (Magnevist, Bayer Healthcare) was administered at 0.1 mmol/kg 
followed by saline flush via teil vein catheter. Coronal post-contrast T1 images were 
obtained. Standard physiologic monitoring occurred during imaging procedure. Animals 
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were recovered and returned to standard housing. Mice were reimaged each week until time 
of sacrifice due to 20% weight loss or signs of tumor burden.
Utilizing the T1 MR 20th and 3rd scan of the dynamic sequence, a difference map was 
generated and Relative Enhancement was calculated as follows:
where Δ[Gd]T and Δ[Gd]P represent contrast concentration changes in tissue and plasma 
during time zero and t, respectively, ST(t) is signal intensity in selected tissue (tumor, 
contralateral normal appearing brain tissue or left lateral ventricular choroid plexus) at time 
point t, SP(t) is signal intensity in plasma at time point t and ST0 and SP0 are pre-contrast 
signal intensity in selected tissue or plasma, respectively.
Multiple regions of interest (ROIs) sized 10–15 pixel (0.1 mm2) were manually drawn by 
one blinded reader on T2 images, guided by the lesion shape, avoiding macroscopic vessels, 
necrosis, and areas of hemorrhage. Region with greatest signal change was selected as the 
tumor ROI. ROIs were propogated to the subtracted T1 DCE MR images, acquired in 
anatomic registration. The same size ROIs were drawn on contralateral amygdala, choroid 
plexus of the contralateral lateral ventricle, and contralateral posterior facial vein lumen.
Pharmacodynamic study design
In vivo PAR Pharmacodynamic Study—An in vivo PAR assay was performed using 
intracranial tissue from the TNBC SUM149 IC murine model. Animals were divided into 
treatment groups, and drug was administered using doses specified in efficacy studies. At 
harvest, tumors were flash frozen in liquid nitrogen, and stored at −80°C until further 
analysis. Net PAR levels were determined in SUM149 IC tumors collected immediately 
following 14 days of treatment with either control or ABT888. To determine net PAR levels 
in the protein extracts from intracranial tumors, a high throughput chemiluminescent ELISA 
PARP in vivo Pharmacodynamic Assay was performed (Trevigen, Gatherburg, MD). Frozen 
SUM149 IC tumors from Control (n=11) or ABT888 (n=8) were homogenized in Lysis 
buffer, sonicated 3 times for 10 seconds each, and assayed for PAR according to the 
manufacturer’s protocol. Luminescence signal of the experimental samples and PAR 
standards were recorded in photons/sec using an IVIS Lumina camera (Caliper Life 
Sciences, Hopkinton, MA) and corrected for background. PAR concentrations in the 
experimental samples were calculated using a standard curve, and PAR levels were 
determined as pg/100ug of total protein. Experimental samples and freshly made PAR 
standards were assayed in triplicate. The assay was repeated once for samples with sufficient 
amount of protein extract. Concentration of the total protein in the extract was measured 
using the BCA Assay (Thermo Fisher Scientific, Rockford, IL).
In vitro PAR Pharmacodynamic Assay—To examine the ability of ABT888 to inhibit 
PAR independently of BRCA status, in vitro PAR levels of BRCA-mut SUM149 and BRCA-
wt MDA-MB-231BR was examined at the IC50 of the SUM149 cell line (60 uM). SUM149 
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and MDA-MB-231BR cells were plated at 1.5 and 1.0 million cells/6 cm dish respectively 
in triplicate. After 24 hours, media was changed to either ABT888 (60 uM) or 0.1% DMSO 
vehicle control. After 2 hours of inhibition, cells were harvested, and PAR was measured 
according to ELISA PARP in vivo Pharmacodynamic Assay protocol (Trevigen, 
Gatherburg, MD).
Immunohistochemistry Study Design and Tissue Preparation
For immunohistochemistry, we collected tissue from BRCA-mut SUM149 and BRCA-wt 
MDA-MB-468 TNBC intracranial murine models. Animals were divided into treatment 
groups within each model and treated for 14 days after tumor injection with 3 doses of 
Carboplatin, 15 doses of ABT888, or Carboplatin+ABT888 in combination. Brain tissues 
from 3 animals per group were collected in formalin the day following last dose of 
Carboplatin and/or immediately after the last dose of ABT888. Whole mouse brains fixed in 
formalin were cut parasagittaly approximately 2mm of midline, incubated in 70% Ethanol, 
embedded in paraffin, and sectioned immediately prior to staining.
Immunohistochemical Staining for γ-H2AX and cleaved Caspase-3
The following antibodies were used to stain 4 μm sections placed on coated glass slides: 
Rabbit monoclonal anti-phospho-ser139-H2AX [γ-H2AX] (1:2000, 2h, Cell Signaling 
Technology, Danvers, MA), rabbit polyclonal Cleaved Caspase-3 [cC3] (1:50, 1h, Biocare 
Medical, Concord, CA). Staining was performed as previously described (21, 22). IHC was 
carried out on the Bond Autostainer, and all solutions were from Leica Microsystems 
(Norwell, MA). Briefly, slides were deparaffinized in Bond dewax solution (AR9222) and 
hydrated in Bond wash solution (AR9590). Antigen retrieval of γ-H2AX was performed for 
30 min at 100°C in Bond-epitope retrieval solution 1 pH-6.0 (AR9961) and in solution 2 
pH-9.0 (AR9640) for cC3. After incubation with the appropriate antibody, detection was 
performed with the Bond Polymer Refine Detection System (DS9800). Stained slides were 
dehydrated and coverslipped. Positive and negative (no primary antibody) controls were 
included for each antibody. Sections from 2–3 biological replicas and 2–3 technical replicas 
(total 6 sections) per treatment group were stained.
Digital imaging and image analysis of immunohistochemical staining
H&E and IHC stained sections were digitally imaged (20× objective) using Aperio 
ScanScope XT (Aperio Technologies, Vista, CA),and analyzed within the Aperio Spectrum 
Database. Folded tissues, non-tumor areas, and artifacts were excluded from the analysis 
using a negative pen. Tumor area identification was guided by H&E staining of an adjacent 
section. The expression of γ-H2AX and cleaved Caspase-3 (cC3) was measured using the 
Aperio Nuclear V9 (cell quantification) algorithm. Positive and negative (no primary 
antibody) controls were included for each antibody. The intensity score and percentage of γ-
H2AX-positive nuclei in the tumor area obtained with the modified nuclear v9 algorithm at 
each intensity level were used to calculate the H-Score using the formula: 
. The H-Score was normalized to a 
γ-H2AX positive SK-MEL 181 cell line control included in each staining. Expression of 
cC3 protein was calculated using the percentage of cC3-positive nuclei.
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Microarrays and RNA purification
RNA from BRCA-mutant intracranial SUM149 and MDA-MB-436 tumors was purified 
using the RNeasy Mini kit (Qiagen, Germantown, MD) following the manufacturer’s 
protocol, labeled as previously described (23), amplification incorporating cyanine-5 (Cy5) 
dye for the tumor samples and cyanine-3 (Cy3) dye for the reference (24) using Agilent Low 
RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies, Santa Clara, CA), 
and hybridized to 4×44K Customized Human Oligomicroarrays (Agilent Technologies, 
Santa Clara, CA). Arrays were scanned with either the Agilent Scanner (Agilent 
Technologies, Santa Clara, CA) or the GenePix Scanner (Molecular Devices, Sunnyvale, 
CA) as previously described (25). All microarray data has been deposited in the Gene 
Expression Omnibus (GEO) under the accession number GSE55399.
SUM149 arrays scanned with the GenePix scanner were normalized to be comparable to the 
Agilent scanner were adjusted according to Supplemental Methods (Supplemental Figure 
S1). Principle component analysis demonstrates effective removal of scanner bias 
(Supplemental Figure S2). Treatment specific gene sets were identified using R v3.0.2 and 
the two class unpaired significance analysis of microarray (SAM) (v3.11) (26) and as further 
described in Supplemental Methods (Supplemental Figure S3). The following comparisons 
were conducted within each model: Control versus Carboplatin, Control versus ABT888, 
Control versus Carboplatin+ABT888, and Carboplatin versus Carboplatin+ABT888 
(Supplemental Tables S1b-S1i). All genes with an FDR = 0 in control versus Carboplatin 
intracranial SUM149 or MDA-MB-436 tumors were analyzed with DAVID (27, 28). 
Pathways are reported with a Bonferroni corrected p value of < 0.05 (Supplemental Tables 
S1j–S1k). For comparative visualization, SUM149 arrays were scaled to the same dynamic 
range as the MDA-MB-436 arrays (Supplemental Figure S4). Unsupervised and supervised 
hierarchical clustering were clustered using centroid linkage in Gene Cluster 3.0 v1.52 (29) 
and viewed with Java Treeview v1.1.6r4 (30).
Statistical Considerations
Results for BBB permeability are reported as mean relative enhancement ± Standard Error 
of Means (SEM). PAR assay results were normalized to the percent of the respective control 
group’s median and are presented as mean of the normalized values ± SEM. IHC to evaluate 
DNA damage and apoptosis is reported as mean values ± SEM. One-way ANOVA tests 
were used to compare mean values between treatment groups using GraphPad Prism 6.04. 
Unpaired t-tests were performed for all pairwise comparisons, with Bonferroni correction 
for multiple comparisons when applicable.
The Kaplan-Meier method and Log-rank tests were used to compare overall survival among 
treatment groups. Mice were censored at pre-specified study endpoints if they had not been 
previously sacrificed. Overall and pair-wise tests were completed, and unadjusted p-values 
are reported. For bioluminescence imaging, fold changes were calculated relative to the start 
date of treatment, and if present, negative imaging values (due to correction for background) 
were recorded and set to zero. The common logarithm of these values were used for this 
analysis. For every time point where at least two animals were alive in the treatment group, 
the median level and interquartile range (25th–75th percentile) for bioluminescence imaging 
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were calculated. For gene expression analysis, significance analysis of microarray was 
employed through R v. 2.15.0 (31).
Results
Our preclinical study evaluates efficacy of Carboplatin therapy as a single agent and in 
combination with the PARP inhibitor, ABT888, in intracranial (IC) orthotopic murine 
models of BRCA-mut and BRCA-wild-type TNBC.
Blood brain barrier permeability across models
To assess the inherent differences in therapy accessibility due to the vasculature across all 
IC murine models, we performed MRI with Gadolinium contrast. Because contrast can only 
enter brain tissue where the BBB is disrupted, relative enhancement (RE) estimates the BBB 
permeability. Tumor mean RE for each IC model was not significantly different across 
models (SUM149: 1.081±0.1084; MDA-MB-436: 0.8711±0.1788; MDA-MB-468: 
0.7683±0.2210; MDA-MB-231BR: 0.6835±0.2052; p=.48). In addition, RE was 
significantly higher in all tumors compared to matched normal brain tissue across all models 
(p<0.001; Figure 1A), indicating a similarly compromised, leaky BBB within all IC tumor 
models. There was no significant difference across models within the normal (p=.14), tumor 
(p=.48), and choroid plexus (p=.82) tissues (Figure 1A). The small amount of RE in normal 
tissues is in agreement with previous studies, representing normal cerebral blood volume 
(32). Representative MRI images are shown for each model and demonstrate that the 
morphologic appearance of the IC tumors formed by each model is a similar, focal, 
concentrated mass with defined borders in the right hemisphere in vivo (Figure 1B).
ABT888 inhibits the function of PARP in SUM149 IC tumors
PARP catalyzes the formation of poly(ADP-ribose) (PAR) chains on a variety of proteins 
including PARP itself. To assess penetration of the PARP inhibitor ABT888 across the BBB 
and monitor inhibitory activity, we measured net PAR levels (± SEM) in SUM149 
intracranial tumors following14 days of ABT888 treatment. PAR levels in ABT888-treated 
SUM149 IC tumors (18.76±7.566) were significantly decreased as compared to control 
tumors (119.8±30.37; p=0.0091), indicating 84.3% inhibition and IC tumor exposure with 
ABT888 treatment (Figure 2A).
To assess differences in the ability to form PAR chains in BRCA-mut as compared to BRCA-
wt models, in vitro PAR assays of BRCA-mut SUM149 and BRCA-wt MDA-MB-231BR 
models were performed following 2 hrs of treatment with 60 uM of ABT888. PAR levels in 
SUM149 cells were significantly decreased with ABT888 treatment (5.820±2.044) as 
compared to control (72.89± 14.25; p=0.0002). In parallel, PAR levels in MDA-MB-231BR 
were significantly decreased in ABT888 treated cells (5.518± 2.763) as compared to control 
cells (114.1± 10.01; p<0.0001). Similar percent inhibition was observed between the BRCA-
mut and BRCA-wt cell lines (SUM149: 92.0% inhibition; MDA-MB-231BR: 95.2%) 
(Figure 2B). Taken together, these data demonstrate effective ABT888 penetration into 
intracranial tumor and similar relative inhibition in vitro between a BRCA-mut and BRCA-wt 
model.
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Treatment with Carboplatin alone and in combination with ABT888 improves survival of 
BRCA-mut, but not BRCA-wt, TNBC intracranial models
Recognizing the BBB permeability of Carboplatin and ABT888, the efficacy of platinum 
agents and PARP inhibitors in advanced extracranial BRCA-mutant TNBC, and the potential 
rational therapeutic combination to treat breast cancer brain metastases, we evaluated the 
efficacy of Carboplatin and ABT888 as single agents and in combination in both BRCA-mut 
and BRCA-wt TNBC IC murine models. Median survivals are reported for each model by 
treatment group (Table 1).
In the basal-like BRCA1-mut SUM149 IC model, the median survival of animals treated 
with Carboplatin±ABT888 were both significantly longer then control (Carboplatin: 58 days 
(95% CI 47 to 67 days); Carboplatin+ABT888: 64 days (95% CI 59 to 75 days); Control: 36 
days (95% CI 34 to 40 days); both treatment groups p < 0.0001 relative to control) (Table 1 
and Figure 3A). The difference between median survival of control and single agent 
ABT888 treated animals (39 days (95% CI 30 to 46 days)) was not statistically significant 
(p=0.2). In addition, ABT888 alone was inferior compared to therapies with Carboplatin as a 
single agent (p=0.007) or Carboplatin+ABT888 combination (p=0.0012). Despite theoretical 
promise, the Carboplatin+ABT888 combination therapy exhibited modest improvement of 
survival in comparison to single agent Carboplatin and was not statistically significant 
(p=0.4; Table 1 and Figure 3A). Of note, 2/16 and 2/17 animals from the Carboplatin and 
Carboplatin+ABT888 groups, respectively, remained alive at the pre-specified study 
completion date (12 weeks post-intracranial implantation of tumor cells).
Recognizing the heterogeneity of TNBC, we investigated response to Carboplatin and 
Carboplatin+ABT888 in a second BRCA-mut IC TNBC model, MDA-MB-436. Median 
survival following treatment with Carboplatin alone (86 days (95% CI 61 to undefined)) and 
with combination Carboplatin+ABT888 (Not reached, ≥ 65 days) were both significantly 
longer (both p=0.001) as compared to control (44 days (95% CI 35 to 47 days); Table 1, 
Figure 3B). Single agent ABT888 resulted in a modest survival advantage compared to 
control (57 days (95% CI 44 to 74 days), p=0.03). The addition of ABT888 to Carboplatin 
did not yield a significant improvement in survival in the MDA-MB-436 model compared to 
Carboplatin alone (p=0.2); however, 4/5 animals in the combination group versus 2/5 
animals in the Carboplatin alone group remained alive 12 weeks post cell injection, 
suggesting benefit of the addition of ABT888 to Carboplatin.
To examine the efficacy of Carboplatin and Carboplatin+ABT888 in BRCA-wt intracranial 
TNBC models, we applied the same experimental design to BRCA-wt intracranial TNBC 
models, basal-like MDA-MB-468 and claudin-low MDA-MB-231BR. In contrast to the 
BRCA-mut TNBC intracranial models, neither single agent Carboplatin, ABT888, nor 
combination Carboplatin+ABT888 resulted in an improved median survival compared to 
control in either BRCA-wt TNBC intracranial model (Supplemental Figure S5A and S5B) 
(MDA-MB-468, p=0.8; MDA-MB-231BR, p=0.1).
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Treatment with Carboplatin alone or in combination with ABT888 impairs tumor growth in 
BRCA-mut basal-like TNBC intracranial murine model
In addition to the survival analysis, we examined the effect of treatment with Carboplatin 
alone or in combination with ABT888 on intracranial tumor growth via bioluminescence in 
the BRCA-mut SUM149 model. Consistent with overall survival results, dynamic changes in 
the intracranial tumor growth as measured by median log fold change of the 
bioluminescence signal intensity (photons/second) from the start of the treatment were 
lowest following treatment with Carboplatin+/− ABT888 (Figure 3C). The median log fold-
change in IC tumors treated with either Carboplatin or Carboplatin+ABT888 was similar at 
8 weeks of treatment (median 3.3, Interquartile Range (IQR) 2.85 to 4.14 versus median 
3.32, IQR 2.56 to 3.97, respectively). Although based on small numbers of animals 
remaining, at 10 weeks post treatment, the median log fold change for the Carboplatin
+ABT888 group remained low until the end of the study, while median fold change for the 
Carboplatin single agent group continued to increase over time (Figure 3C).
Treatment with Carboplatin and Carboplatin+ABT888 induces DNA damage and apoptosis 
in BRCA-mutant intracranial tumor but not BRCA-wt intracranial tumors
To investigate whether processes of DNA damage and apoptosis are activated in intracranial 
tumors in response to treatment, we evaluated expression of γ-H2AX protein, a known 
biomarker of DNA damage, and cC3, the central protein in the terminal phase of apoptosis 
(15, 33–35).
Expression of γ-H2AX was elevated in all treatment groups compared to control following 
14 days of treatment in BRCA-mut SUM149 intracranial tumors (Figure 4A, p=0.0106). 
DNA damage was highest in the Carboplatin group (91.0 ± 3.7, p=0.001) followed by 
combination Carboplatin+ABT888 (76.6 ± 8.8, p=0.12), which were both higher than 
control (58.5 ± 6.0). ABT888 treatment resulted in an γ-H2AX H score (75.4 ± 4.3) that was 
higher than control (p=0.045).
With similar BBB permeability observed between the BRCA-wt and BRCA-mut models, 
significant differences in DNA damage were also observed in the BRCA-wt MDA-MB-468 
IC model for both Carboplatin and Carboplatin+ABT888 treated groups as compared to 
control (p=0.0015). Expression of γ-H2AX, however, was notably weaker in the MDA-
MB-468 IC tumors as compared to the SUM149 IC model (p<0.0001 MDA-MB-468 
Control vs SUM149 Control, Figure 4A, 4C, and 4D). Attenuated DNA damage after DNA 
adduct formation rather than differences in exposure to Carboplatin may provide an 
explanation as to why Carboplatin treatment +/− ABT888 was effective in the BRCA-mut 
and not in the BRCA-wt intracranial models.
In addition to γH2AX expression, the same tumor samples from BRCA-mut SUM149 and 
BRCA-wt MDA-MB-468 intracranial models were analysed to determine expression levels 
of cC3 protein. In BRCA-mut SUM149 intracranial tumors, mean percentages of cC3 
positive cells for all treatments were significantly higher in comparison to Control (7.7±0.4, 
p=0.0297, Figure 4B, 4E, and 4F); however, mean percentages of cC3 positive cells (± 
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SEM) by treatment group were not significantly different from each other (ABT888 15.5 ± 
2.6, Carboplatin 12.8 ± 1.5, and Carboplatin+ABT888 12.2 ± 1.5; p=0.46).
In the BRCA-wt MDA-MB-468 intracranial model, mean values of percent cC3 positive 
cells for ABT888 (14.5±2.7), Carboplatin (7.0±2.0), and Carboplatin/ABT888 (13.0±2.0) 
exhibited overall borderline significance when compared to control (8.2±1.3; p=0.051; 
Figure 4B, Supplemental Figure S6).
Taken together, these data support previous findings that BRCA status has a significant 
impact on sensitivity to Carboplatin treatment through increased DNA damage and 
apoptosis levels, and provides a possible explanation as to why BRCA-wt intracranial tumors 
are less responsive to Carboplatin treatment +/− ABT888.
Intracranial TNBC Gene Expression Changes in Response to Carboplatin with and without 
ABT888
To examine the dynamic transcriptional changes that occur in IC tumors in response to 
treatment, we performed gene expression analysis of BRCA-mut IC tumors from mice 
treated with control, ABT888, Carboplatin, and Carboplatin+ABT888 in the BRCA-mut 
basal-like SUM149 and the BRCA-mut claudin-low MDA-MB-436 intracranial models.
Unsupervised hierarchical clustering of all samples identified cell line specific delineations 
as well as distinct clusters defined by Carboplatin treatment +/− ABT888 (Supplemental 
Figure S7). Independent analyses within each model further demonstrated little to no 
contribution with the addition of ABT888 to control or Carboplatin treatments (Figure 5A, 
5B).
To quantitate gene expression changes that occurred with treatment, each treatment group 
was compared to control within SUM149 and separately within MDA-MB-436 tumors 
(Supplemental Tables S1b–S1i). Treatment with ABT888 as compared to control 
(Supplemental Table S1b, S1c) resulted in 19 differentially expressed genes for the SUM149 
model, and 153 differentially expressed genes for the MDA-MB436 model. In contrast, 
comparison of Carboplatin treatment to control (Supplemental Table S1d, S1e) 
demonstrated a substantially higher number of genes differentially expressed within each 
model (Carboplatin vs. Control: SUM149 = 176; MDA-MB-436 = 5125). Supervised 
clustering of these genes reveals consistent gene expression patterns throughout each cluster 
of samples (Supplemental Figure S8A and S8B). Similar results were seen in comparing 
Carboplatin+ABT888 to Control, with 53 genes differentially regulated in SUM149 tumors, 
and 4183 genes altered in MDA-MB-436 tumors (Supplemental Tables S1f, S1g). When 
Carboplatin was compared to Carboplatin+ABT888 treatment, less than 10 differentially 
expressed transcripts were identified, and none were shared between the two models 
(SUM149: n=9; MDA-MB-436 n=2) (Supplemental Tables S1h, S1i). Thus, while not 
inhibiting the ability of Carboplatin to induce dynamic transcriptional changes, ABT888 
minimally changes gene expression when combined with Carboplatin treatment.
To annotate the transcriptional changes occurring with Carboplatin treatment, pathway 
analysis of genes altered with Carboplatin treatment within each model was analyzed with 
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DAVID (27, 28). Up-regulated genes in both SUM149 and MDA-MB-436 were enriched 
for ‘signal peptide’, ‘glycopeptide’, and ‘SH3 domain’ (Supplemental Table S1j). 
Interestingly, in MDA-MB-436, neuronal development, neuronal differentiation, and 
neuronal morphogenesis were significantly up-regulated (Supplemental Table S1j). Down-
regulated pathways in DAVID were only significant in the MDA-MB-436 model, with 16 of 
the top 30 most significant terms involving processes in the mitochondria including 
‘electronic chain transport’, ‘respiratory chain’, and ‘mitochondrial inner membrane’ 
(Supplemental Table S1k).
To define the common transcriptional program that is altered with Carboplatin treatment, the 
intersection of up-regulated and down-regulated genes common to both models was used. 37 
genes were commonly up-regulated (Supplemental Figure S9A), and 1 gene was commonly 
down-regulated (Supplemental Figure S9B) with Carboplatin treatment in SUM149 and 
MDA-MB-436 tumors (Supplemental Figure S9C). Interestingly, we found three oncogenes 
upregulated with Carboplatin treatment, including N-myc (NDRG4), Ras (RAB39B), and Kit, 
and genes previously demonstrated to be potential therapeutic targets in TNBC, including 
αB-crystallin (CRYAB) and folate receptor (FOLR3) (Figure 5C) (36, 37). Additionally, 
multiple neurological genes were up-regulated including CNTNAP2, a member of the 
neurexin family that provides adhesion in the central nervous system (CNS), CES1, a 
possible member of the blood-brain barrier, and two CNS specific G-protein coupled 
receptors, GPR98 and NPY1R (38, 39).
Discussion
This study has demonstrated efficacy of Carboplatin+/−ABT888 treatment in two murine 
models of BRCA-mut intracranial TNBC with little to no efficacy in models of intracranial 
BRCA-wt TNBC despite similar BBB permeability and relative PAR inhibition across both 
BRCA-mut and BRCA-wt models. With confirmed brain penetrance, the addition of PARP 
inhibition to platinum therapy via ABT888 exhibited only modest impact on efficacy as 
measured by tumor burden, survival, and molecular changes within the intracranial tumors 
themselves.
In BRCA-mut intracranial TNBC models, Carboplatin treatment not only resulted in 
reduction of intracranial tumor volume, but in several cases, in growth arrest of intracranial 
tumors as evidenced by bioluminescence imaging. The mechanism of increased cytotoxicity 
within BRCA-mut intracranial TNBC is hypothesized to be a failure to effectively repair 
DNA damage induced by Carboplatin due to impaired homologous recombination (HR) 
repair pathways with BRCA loss of function (9). This hypothesis is confirmed by 
augumentation of γ-H2AX activation and apoptosis mediated by increased levels of cC3 
following treatment with Carboplatin. Interestingly, the addition of a PARP inhibitor, which 
impairs base excision repair, failed to yield a significant survival benefit as a single agent in 
these model systems. Moreover, the PARP inhibitor did not induce widespread or common 
gene expression alterations in the BRCA-mut models either alone or when combined with 
Carboplatin. In contrast, Carboplatin treatment led to substantial gene expression changes 
observed in BRCA-mut SUM149 and BRCA-mut MDA-MB-436 intracranial models with 37 
genes commonly up-regulated, suggesting possible compensatory pathways that are 
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activated upon treatment with Carboplatin. These included oncogenes, previously described 
brain metastasis therapeutic targets, and neural genes. Interestingly, several recent studies 
report similar upregulation of neural genes in breast cancer brain metastases including genes 
related to GABA (40), cellular adhesion (41), and several neurobiological functions (42, 43). 
While our results could be due in part to normal mouse brain contamination, these 
complementary and recent studies have excluded this caveat by assessing expression in 
purified tumor cells (40), passaging metastases cells in vitro (42), or by using species-
specific microarrays (44). Exploration of potentially targetable upregulated genes in 
combination with Carboplatin treatment that are low or absent in normal brain tissue will be 
critical to future rational combination therapies to avoid neurological side-effects.
Our results demonstrate efficacy of well-tolerated therapeutics in model systems for a 
patient population with few treatment options. Currently in the field of TNBC brain 
metastases, a lack of therapeutic targets leaves clinicians with few beneficial choices aside 
from neurosurgical resection or crainal radiation. In addition, TNBC brain metastases are 
commonly (>80% of the time) accompanied by extracranial metastases, warranting effective 
systemic therapies capable of controlling both CNS and non-CNS disease (4). Other studies 
have demonstrated that irinotecan and iniparib yield an approximately 30% clinical benefit 
rate in patients with progressive TNBC brain metastases (45). In addition, a recent phase II 
study showed an approximately 65% intracranial response rate as measured by volumetric 
imaging following treatment with Carboplatin and Bevacizumab in patients with progressive 
HER2 negative brain metastases (46). Despite these promising results, there remains no 
FDA-approved systemic therapy for TNBC brain metastases. Our data continues to support 
the role of Carboplatin for the treatment of breast cancer brain metastases, specifically in 
TNBC with BRCA mutations, and the rationale of using Carboplatin±ABT888 combination 
in the clinical setting to determine whether ABT888 provides an additional benefit in 
patients with brain metastases.
While our study adds to the literature surrounding TNBC brain metastases treatment, there 
are several limitations to our study. Direct intracranial implantation, as opposed to 
hematogenous spread of tumor cells to the CNS, may not recapitulate human spread of 
metastases; however, the purpose of this study was to evaluate established brain metastases, 
not prevention, in response to drug delivery and its impact on the intracranial tumor. 
Additionally, while ABT888 reduced PAR levels in intracranial tumors, suggesting effective 
BBB penetration, limited efficacy and few gene expression changes were observed. Future 
studies may aim to investigate other PARP inhibitors with varying degrees of catalytic 
activity, and thus may be more effective and synergistic with Carboplatin treatment in brain 
metastases (47).
In conclusion, to our knowledge this study is the first to demonstrate a significant survival 
advantage in response to systemic Carboplatinn+/−ABT888 treatment in BRCA-mut TNBC 
intracranial murine models, as well as a mechanistic explanation of these results. Moreover, 
we have shown that PARP inhibition as a single agent, while effectively penetrating the 
BBB, does not yield significant improvement in survival or have a dynamic impact on gene 
expression. These results provide strong rationale to translate our findings into the design of 
early phase clinical trials for patients with BRCA-mut TNBC brain metastases testing 
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Carboplatin+/−ABT888, with the ultimate goal of improving the survival of patients with an 
incurable disease who, at present, have limited systemic therapeutic options.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Blood brain barrier (BBB) permeability studies demonstrate compromised BBB in 
tumors as compared to normal brain and no significant differences in BBB permeability between 
models
(A) Relative enhancement of four tumor cell lines with matched normal, tumor, and choroid 
plexus as determined from T1 DCE MR images, formed from digitally subtracting pre-
contrast T1-DCE-weighted sequence from the identical sequence performed after 
gadolinium administration (20th sequence). Significant difference was observed between 
tumor and normal brain tissue (p<0.001), and no significant difference was seen between 
models within each tissue type (p>.14 within each tissue). (B) Brain MR imaging of a 
preresentative intracranial tumor from each of the four intracranial models.
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Figure 2. Formation of poly(ADP-ribose) chain fragments [PAR] indicates intracranial exposure 
for ABT888 and significant in vitro inhibition regardless of BRCA status
A. Relative net PAR levels measured in the SUM149 intracranial tumor tissue after 
treatment with PBS control or ABT888 for 14 days. PAR levels decreased from 
119.8±30.37 to 18.76±7.57 following ABT888 treatment (p<0.0001). Data are expressed as 
the percentage of the mean control tumor mean PAR values (±SEM), normalized to the total 
amount of protein in the sample protein extract (pg/ml per 100ug total protein).
B. PAR levels measured in cell culture of BRCA-mut SUM149 and BRCA-wt MDA-
MB-231BR following 2h ABT888 treatment. SUM149 control treated (72.89±14.25) as 
compared to ABT888 treated (5.820±2.044) and MDA-MB-231BR control (114.1±10.01) as 
compared to ABT888 treated (5.518±2.763) are significantly decreased (SUM149: 
p<0.0002; MDA-MB-231BR: p<0.0001).
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Figure 3. Treatment with Carboplatin +/− ABT888 improves survival in BRCA-mutant 
intracranial TNBC
Animals in both models were treated with PBS (control), Carboplatin 50mg/kg/week (IP), 
ABT888 25mg/kg/day (OG) or combination Carboplatin+ABT888 (doses as in single agent 
therapy). Treatment began 14 days after intracranial implantation. A total of 4 animals in the 
SUM149 model and a total of 6 animals in the MDA-MB436 model treated with 
Carboplatin and Carboplatin+ABT888 were sacrificed 12 weeks post-intracranial 
implantation, as defined by IAUCUC protocol guidelines, and were censored for the purpose 
of the analysis.
A. Median survival of the SUM149 intracranial model.
B. Median survival of the MDA-MB-436 intracranial model.
C. Dynamic changes in intracranial tumor growth measured by median fold change of the 
bioluminescence signal intensity from the start of the treatment in SUM149 TNBC murine 
model. The median log fold changes for each treatment group were calculated weekly. Data 
for each time point were plotted if at least 2 animals per treatment group remained alive. The 
vertical bars represent the interquartile ranges (25th–75th percentiles).
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Figure 4. Immunohistochemical staining to evaluate DNA damage and apoptosis via γ-H2AX 
and Cleaved Caspase-3 Protein Expression in BRCA-mutant and BRCA-wild-type intracranial 
TNBC
Gamma-H2AX [γ-H2AX] (A) and cleaved Caspase-3 [cC3] (B) protein expression in 
BRCA-mutant SUM149 and BRCA wild-type MDA-MB-468 intracranial tumors evaluated 
after 14 days of treatment in PBS control, ABT888, Carboplatin, Carboplatin+ABT888 
groups by IHC staining. Data are presented as H-Score mean values (±SEM) for γ-H2AX 
protein expression, and as mean percentage (±SEM) of cC3 positive cells to reflect cC3 
protein expression. p values of all treatment groups compared to Control are presented for 
each model. Representative sections stained with γ-H2AX after treatment with Carboplatin 
are displayed for SUM149 model (C) and MDA-MB468 model (D), magnification 10×.
Representative sections stained with cC3 after treatment with PBS (control, E) or 
Carboplatin (F) are displayed for SUM149 model (magnification 20×, zoom 10×).
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Figure 5. Gene expression changes of Carboplatin-sensitive SUM149 and MDA-MB-436 TNBC 
intracranial tumors
Measured expression patterns of tumors treated within the BRCA-mutant models, with up-
regulated genes in red and down-regulated genes in green. Unsupervised hierarchical 
clustering of the most highly differentiating genes within the (A) MDA-MB-436 (purple) 
and (B) SUM149 (yellow) tumors stratified by Carboplatin treatment (red), Carboplatin
+ABT888 (blue), ABT888 alone (green), or Control (black). (C) Supervised clustering using 
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the 38 commonly altered genes with Carboplatin treatment across all tumors. Color bars 
mark oncogenes (orange), therapeutic targets (gray), and nervous system genes (light blue).
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